Clinical Trial Update: A Study of First-Line Ambrisentan and Tadalafil Combination Therapy in Subjects With Pulmonary Arterial Hypertension (PAH) [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating first-line ambrisentan and tadalafil combination therapy in pulmonary arterial hypertension has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pulmonary Arterial Hypertension

Drugs mentioned

• ambrisentan and tadalafil combination therapy

Snippet

Sponsor: GlaxoSmithKline | Conditions: Hypertension, Pulmonary | Phase 3 | Status: COMPLETED | Results posted: 2015-04-28